Syros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.40), $0.07 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $4.92 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.